Hybrid business models for ‘Organ-on-a-Chip’ technology: The best of both worlds

Burgwal, Linda van de; Dorst, Pim van; Viëtor, Henk E.; Lüttge, Regina; Claassen, Eric

doi:10.1016/j.phanu.2018.02.001

Cited by 13 publications

(19 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The OoC can reproduce particular conditions, such as the presence of specific pathologies, age and sex differences, or metabolic modifications [3,7,8,15,[42][43][44]. The ability of OoC systems to mimic the functionality of an organ allows to visualize the impact of a condition on the organ's function.…”

Section: Ooc Basic Featuresmentioning

confidence: 99%

“…The development of these models brought to the emergence of an industry with more than 28 companies founded in 7 years [7,17,18]. Hundreds of publications are generated each year regarding this topic, which rises the interest of companies carrying out basic research in the field of drugs and also in other areas such as cosmetics, food and medical devices [8,11,[19][20][21][22]. Some of the synonyms under which OoC can be found in the literature are the following ones: lab-on-achip [17], organoids-on-chip [23], organ-on-a-plate [6], tissue-on-chip [9], microphysiological system (MPS) [6], and MPS-based organ model [24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Organ-on-a-Chip systems for new drugs development

2021

View full text Add to dashboard Cite

Research on alternatives to the use of animal models and cell cultures has led to the creation of organ-on-a-chip systems, in which organs and their physiological reactions to the presence of external stimuli are simulated. These systems could even replace the use of human beings as subjects for the study of drugs in clinical phases and have an impact on personalized therapies. Organ-on-a-chip technology present higher potential than traditional cell cultures for an appropriate prediction of functional impairments, appearance of adverse effects, the pharmacokinetic and toxicological profile and the efficacy of a drug. This potential is given by the possibility of placing different cell lines in a three-dimensional-arranged polymer piece and simulating and controlling specific conditions. Thus, the normal functioning of an organ, tissue, barrier, or physiological phenomenon can be simulated, as well as the interrelation between different systems. Furthermore, this alternative allows the study of physiological and pathophysiological processes. Its design combines different disciplines such as materials engineering, cell cultures, microfluidics and physiology, among others. This work presents the main considerations of OoC systems, the materials, methods and cell lines used for their design, and the conditions required for their proper functioning. Examples of applications and main challenges for the development of more robust systems are shown. This non-systematic review is intended to be a reference framework that facilitates research focused on the development of new OoC systems, as well as their use as alternatives in pharmacological, pharmacokinetic and toxicological studies.

show abstract

Section: Ooc Basic Featuresmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Organ-on-a-Chip systems for new drugs development

2021

View full text Add to dashboard Cite

show abstract

“…Conventional in vitro and in vivo models will be replaced by these new preclinical technologies. The commercial interest in organ-ona-chip technology is growing, and the market for this technology is estimated to reach six billion dollars in about 5 years [128].…”

Section: Future Prospectsmentioning

confidence: 99%

Microfluidic Devices: A New Paradigm in Toxicity Studies

Boşgelmez

İçöz

Yiğit

2020

Hacettepe Journal of Biology and Chemistry

View full text Add to dashboard Cite

S on yıllarda, 3R (yerine koyma, azaltma, iyileştirme) prensibi doğrultusunda deney hayvanı kullanımını azaltmak için alternatif toksikoloji metotlarına (örneğin, in vitro modeller, in silico veya −omics verilerine) büyük önem verilmektedir. Bu metotlar, yeni ilaçların keşfedilmesiyle ilişkili preklinik etkinlik ve güvenliğin hızlı ve doğru bir şekilde tahmin edilmesine ve klinik çalışmalarda başarısızlık oranlarının azaltılmasına yardımcı olmaktadır. Günümüzde in vitro çalışmalar; iki boyutlu (2D) hücre kültürlerinden, doku, organ ve hatta organizmanın fizyolojisini taklit edebilen üç boyutlu (3D) hücre kültürlerine dönüşüm veya değişim içindedir.Bu bağlamda, 3D kültür modellerinin gelişmekte olan mikroakışkan teknolojilerine entegrasyonu ile çip-üstü-organ sistemleri geliştirilmiştir. Çip-üstü-organ sistemleri, ilaç araştırma ve geliştirme (Ar-Ge) sürecinde doz-yanıt ve toksisite mekanizmalarının iyi anlaşılmasını sağladığı için, ksenobiyotiklerin insan vücudu üzerindeki etkisinin tatmin edici düzeyde tahmin edilmesi mümkün olmaktadır. Ayrıca, bu sistemler farmakokinetik-farmakodinamik parametrelerin ve ilaç direncinin değerlendirilmesini destekleyebilir. Modeller, test edilen ksenobiyotiğe yanıtı incelemek için "çip-üstü-hastalık modelleri" şeklinde veya sağlıklı hücrelerle üretilebilir.Bu derleme kapsamında; çip-üstü-organ sistemlerinde kullanılan mikroakışkan sistemleri ele alınmakta ve karaciğer, böbrek, beyin, akciğer, kalp ve bağırsaklar gibi çeşitli örneklerin mikro-ortamlarının ve fizyolojik özelliklerinin çip-üstü-organ modellerine yansıtıldığı toksisite çalışmaları için potansiyelleri vurgulanmaktadır.

show abstract

“…A key factor to a linear technology development pathway is to define the value proposition, to promptly transition from an R&D-only stage to the validation phase, and finally move to optimization and scale-up for rapid adoption. These steps are necessary to deliver the promised benefits and to successfully exploit funding sources and investments [5]. Mistakes and delays along this path lead to continuous technological challenges and revisions of the business model, but most importantly, risk attenuating the interest of end-users and reduce future funding opportunities.…”

Section: Introductionmentioning

confidence: 99%

Translational Roadmap for the Organs-on-a-Chip Industry toward Broad Adoption

et al. 2020

View full text Add to dashboard Cite

Organs-on-a-Chip (OOAC) is a disruptive technology with widely recognized potential to change the efficiency, effectiveness, and costs of the drug discovery process; to advance insights into human biology; to enable clinical research where human trials are not feasible. However, further development is needed for the successful adoption and acceptance of this technology. Areas for improvement include technological maturity, more robust validation of translational and predictive in vivo-like biology, and requirements of tighter quality standards for commercial viability. In this review, we reported on the consensus around existing challenges and necessary performance benchmarks that are required toward the broader adoption of OOACs in the next five years, and we defined a potential roadmap for future translational development of OOAC technology. We provided a clear snapshot of the current developmental stage of OOAC commercialization, including existing platforms, ancillary technologies, and tools required for the use of OOAC devices, and analyze their technology readiness levels. Using data gathered from OOAC developers and end-users, we identified prevalent challenges faced by the community, strategic trends and requirements driving OOAC technology development, and existing technological bottlenecks that could be outsourced or leveraged by active collaborations with academia.

show abstract

Hybrid business models for ‘Organ-on-a-Chip’ technology: The best of both worlds

Cited by 13 publications

References 55 publications

Organ-on-a-Chip systems for new drugs development

Organ-on-a-Chip systems for new drugs development

Microfluidic Devices: A New Paradigm in Toxicity Studies

Translational Roadmap for the Organs-on-a-Chip Industry toward Broad Adoption

Contact Info

Product

Resources

About